64Cu治疗计划与67Cu治疗:放射性标记[64Cu/67Cu]MeCOSar-奥曲肽在不可切除多灶性脑膜瘤受试者中的人体显像、安全性、生物分布与辐射剂量学初步结果
在5例不可切除多灶性脑膜瘤受试者中,先以[64Cu]Cu-SARTATE行PET/CT显像并用OLINDA/EXM估算正常器官剂量,其中3例随后接受4个周期[67Cu]Cu-SARTATE治疗并多次SPECT/CT显像。未观察到严重不良事件,无不良事件导致退出研究或终止治疗;[64Cu]Cu-SARTATE与[67Cu]Cu-SARTATE的估算平均有效剂量分别为3.95×10-2 mSv/MBq和7.62×10-2 mSv/MBq。
要点
- 5例受试者治疗前接受[64Cu]Cu-SARTATE PET/CT显像,其中3例接受4个周期[67Cu]Cu-SARTATE治疗。
- 未观察到严重不良事件,无不良事件导致退出研究或终止治疗。
- 脾脏估算器官剂量最高,其次为肾脏、肝脏、肾上腺和小肠。
核心结论
- 64Cu与67Cu作为治疗诊断放射性核素对显示出很大前景。
- 尚需进一步临床研究以考察[67Cu]Cu-SARTATE用于不同适应证所需的治疗剂量。
- 应进一步探索利用基于64Cu的预测剂量学为67Cu治疗计划服务的能力。
研究设计与样本
- 研究在表达生长抑素受体的颅内病灶受试者中使用螯合剂MeCOSar(SARTATE)偶联奥曲肽,以64Cu和67Cu作为治疗诊断放射性核素对。
- 治疗前于注射[64Cu]Cu-SARTATE后至24小时行PET显像,并用OLINDA/EXM估算正常器官剂量。
- 随后对多灶性脑膜瘤受试者给予[67Cu]Cu-SARTATE治疗剂量,并在数日内用SPECT/CT显像。
主要发现
- 最初招募5例受试者并在治疗前用PET/CT显像。
- 其中3例受试者随后各接受4个周期[67Cu]Cu-SARTATE,并完成多个SPECT/CT显像时间点。
- 未观察到严重不良事件,无不良事件导致退出研究或终止治疗。
- [64Cu]Cu-SARTATE估算平均有效剂量为3.95×10-2 mSv/MBq,[67Cu]Cu-SARTATE为7.62×10-2 mSv/MBq。
- 估算器官剂量最高为脾脏,其次为肾脏、肝脏、肾上腺和小肠。
关键数值与推荐
- PET与SPECT同受试者显像显示匹配配对对肿瘤靶向几乎一致,可用于指导治疗。
- [64Cu]Cu-SARTATE估算平均有效剂量为3.95×10-2 mSv/MBq。
- [67Cu]Cu-SARTATE估算平均有效剂量为7.62×10-2 mSv/MBq。
临床怎么用
- 作者认为64Cu与67Cu作为治疗诊断放射性核素对显示出很大前景。
- 作者指出尚需进一步临床研究以考察[67Cu]Cu-SARTATE用于不同适应证所需的治疗剂量。
- 作者认为应进一步探索利用基于64Cu的预测剂量学为67Cu治疗计划服务的能力。
局限性
- 作者指出尚需进一步临床研究以考察[67Cu]Cu-SARTATE用于不同适应证所需的治疗剂量。
- 作者指出应进一步探索利用基于64Cu的预测剂量学为67Cu治疗计划服务的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our aim was to report the use of 64Cu and 67Cu as a theranostic pair of radionuclides in human subjects. An additional aim was to measure whole-organ dosimetry of 64Cu and 67Cu attached to the somatostatin analog octreotate using the sarcophagine MeCOSar chelator (SARTATE) in subjects with somatostatin receptor-expressing lesions confined to the cranium, thereby permitting normal-organ dosimetry for the remainder of the body. Methods: Pretreatment PET imaging studies were performed up to 24 h after injection of [64Cu]Cu-SARTATE, and normal-organ dosimetry was estimated using OLINDA/EXM. Subsequently, the trial subjects with multifocal meningiomas were given therapeutic doses of [67Cu]Cu-SARTATE and imaged over several days using SPECT/CT. Results: Five subjects were initially recruited and imaged using PET/CT before treatment. Three of the subjects were subsequently administered 4 cycles each of [67Cu]Cu-SARTATE followed by multiple SPECT/CT imaging time points. No serious adverse events were observed, and no adverse events led to withdrawal from the study or discontinuation from treatment. The estimated mean effective dose was 3.95 × 10-2 mSv/MBq for [64Cu]Cu-SARTATE and 7.62 × 10-2 mSv/MBq for [67Cu]Cu-SARTATE. The highest estimated organ dose was in spleen, followed by kidneys, liver, adrenals, and small intestine. The matched pairing was shown by PET and SPECT intrasubject imaging to have nearly identical targeting to tumors for guiding therapy, demonstrating a potentially accurate and precise theranostic product. Conclusion: 64Cu and 67Cu show great promise as a theranostic pair of radionuclides. Further clinical studies will be required to examine the therapeutic dose required for [67Cu]Cu-SARTATE for various indications. In addition, the ability to use predictive 64Cu-based dosimetry for treatment planning with 67Cu should be further explored.
引用
- Bailey DL, Willowson KP, Harris M, et al. 64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry. J Nucl Med. 2022. PMID: 36460344. doi:10.2967/jnumed.122.264586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。